Fibroblast response to gadolinium: Role for platelet-derived growth factor receptor

Investigative Radiology

Volumn 45, Issue 12, 2010, Pages 769-777

  Bhagavathula, Narasimharao ^a   Dame, Michael K ^a   DaSilva, Marissa ^a   Jenkins, William ^a   Aslam, Muhammad N ^a   Perone, Patricia ^a   Varani, James ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Fibroblast; Gadolinium; Matrix metalloproteinase 1 (MMP 1); Platelet derived growth factor (PDGF BB); Tissue inhibitor of metalloproteinases 1 (TIMP 1)

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; COLLAGEN TYPE 1; GADODIAMIDE; GADOLINIUM; INTERSTITIAL COLLAGENASE; LANTHANIDE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; UO 126;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DERMIS; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FIBROBLAST CULTURE; HISTOLOGY; HUMAN; HUMAN CELL; MONOLAYER CULTURE; NEPHROGENIC SYSTEMIC FIBROSIS; NORMAL HUMAN; ORGAN CULTURE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN; SKIN FIBROBLAST; WESTERN BLOTTING;

EID: 78650679876     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181e943d2     Document Type: Article

References (64)

1. Evans CH, ed. Biochemistry of the Lanthanides. New York, NY: Plenum Press; 1990.
2. Pidcock E, Moore GR. Structural characteristics of protein binding sites for calcium and lanthanide ions. J Biol Inorg Chem. 2001;6:479-489.
3. 2+ response. Biochemistry. 2009;48:388-398.
4. Kallay E, Bajna E, Wrba F, et al. Dietary calcium and growth modulation of human colon cancer cells: role of the extracellular calcium-sensing receptor. Cancer Detect Prev. 2000;24:127-136.
5. Preeta R, Nair RR. Stimulation of cardiac fibroblast proliferation by cerium: a superoxide anion-mediated response. J Mol Cell Cardiol. 1999;31:1573-1580.
6. Nair RR, Preeta R, Smith G, et al. Variation in mitogenic response of cardiac and pulmonary fibroblasts to cerium. Biol Trace Elem Res. 2003;94:237-246.
7. Kumar BP, Shivakumar K, Kartha CC, et al. Magenesium deficiency and cerium promote fibrogenesis in rat heart. Bull Environ Contam Toxicol. 1996;57:517-524.
8. Valiathan MS, Karha CC, Eapen JT, et al. A geochemical basis for endomyocardial fibrosis. Cardiovasc Res. 1989;23:647-648.
9. Valiathan MS, Kartha CC. Endomyocardial fibrosis-the possible connection with myocardial levels of magnesium and cerium. Int J Cardiol. 1990;28:1-5.
10. 3+-induced extracellular signal-regulated kinase (ERK) signaling via a metal-sensing mechanism linking proliferation and apoptosis in NIH 3T3 cells. Biochemistry. 2006;45:11217-11223.
11. Yu S, Hu J, Yang X, et al. Lanthanum induces extracellular signal-regulated kinase phosphorylation through different mechanisms in HeLa cells and NIH 3T3 cells. Biometals. 2006;19:13-18.
12. Haley TJ, Komesu N, Efros M, et al. Pharmacology and toxicology of lutetium chloride. J Pharm Sci. 2006;53:1186-1188.
13. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000-1001.
14. Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563-572.
15. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108.
16. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362.
17. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol. 2007;42:139-145.
18. Rydahl C, Thomsen HS, Marckmann R. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
19. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. Am J Radiol. 2008;190:736-741.
20. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:191-199.
21. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentate dimeglumine. Invest Radiol. 2009;44:135-139.
22. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol. 2009;44:74-81.
23. Bhagavathula N, DaSilva M, Aslam MN, et al. Regulation of collagen turn over in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol. 2009;45:15-23.
24. Perone P, Weber S, DaSilva M, et al. Collagenase activity is suppressed by elevated tissue inhibitor of metalloproteinase-1 (TIMP-1) in human skin exposed to a gadolinium-based MRI contrast agent. Invest Radiol. 2010;45: 42-48.
25. Spencer A, Wilson S, Harpur E. Gadolinium chloride toxicity in the mouse. Hum Exp Toxicol. 1998;17:633-637.
26. Kubota Y, Takahashi S, Takahashi I, et al. Different cytotoxic response to gadolinium between mouse and rat alveolar macrophages. Toxicol In Vitro. 2000;14:309-319.
27. Varani J, Perone P, Griffiths CEM, et al. All-trans retinoic acid (RA) stimulates events in organ-cultured human skin that underlie repair. Adult skin from sun-protected and sun-exposed sites responds in an identical manner to RA while neonatal foreskin responds differently. J Clin Invest. 1994;94:1747-1756.
28. Perone P, Fay K, Varani J. MDI-301, a non-irritating retinoid, induces changes in human skin that underlie repair. Arch Dermatol Res. 2007;298: 439-448.
29. Lateef H, Stevens MJ, Varani J. All-trans-retinoic acid suppresses matrix metalloproteinase activity and increases collagen synthesis in diabetic human skin in organ culture. Am J Pathol. 2004;165:167-174.
30. Vanlaethem J. Transforming growth factor beta promotes development of fibrosis after repeated courses of acute pancreatitis in mice. Gastroenterology. 1996;110:576-582.
31. Cutroneo KR, White SL, Phan SH, et al. Therapies for bleomycin induced lung fibrosis through regulation of TGF-β1 induced collagen gene expression. J Cell Physiol. 2007;211:585-589.
32. 2+ as an extracellular signal in bone. Cell Calcium. 2004;35:249-255.
33. Li L, Asteriou T, Bernert B, et al. Growth factor regulation of hyaluronan synthesis and degradation in human dermal fibroblasts: importance of hyaluronan for the mitogenic response to PDGF-BB. Biochem J. 2007;404:327-336.
34. DaSilva M, O'Brien Deming M, Fligiel SEG, et al. Responses of human skin in organ culture to a gadolinium-based MRI contrast agent. Comparison of skin from patients in end-stage renal failure with skin from healthy subjects. Invest Radiol. 2010;45:733-739.
35. Canty EG, Kadler KE. Commentary: procollagen trafficking, processing and fibrillogenesis. J Cell Sci. 2005;118:1341-1353.
36. Evans CH, Drouven BJ. The promotion of collagen polymerization by lanthanide and calcium ions. Biochem J. 1983;213:751-758.
37. Drouven BJ, Evans CH. Collagen fibrillogenesis in the presence of lanthanides. J Biol Chem. 1986;261:11792-11797.
38. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol. 2008;214:584-593.
39. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol. 2008;66:175-179.
40. Lin SP, Brown JJ. MR contrast agents: physical and pharmacological basics. J Magn Reson Imaging. 2007;25:884-899.
41. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadoliniumbased contrast media. Invest Radiol. 2008;43:65-75.
42. Sieber MA, Lengsfeld P, Walter J, et al. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging. 2008;27:955-962.
43. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008;18:2164-2173.
44. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009;44: 226-233.
45. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol. 2008;43:817-828.
46. 3 and Gd-DTPA and their influence on proton magnetic relaxation in rat tissues. Magn Reson Imaging. 1987;5:221-231.
47. McNeill AM, Barr RJ. Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int J Dermatol. 2002;41:364-367.
48. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58:2543-2548.
49. Swaninathan S, Arbiser JL, Hiatt KM, et al. Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-s6 kinase. J Am Acad Dermatol. 2010;62:343-345.
50. Patterson JW. The perforating disorders. J Am Acad Dermatol. 1984;10:561-581.
51. Randle HW. Keratotic papules of chronic renal failure: the process of transepithelial elimination. Arch Dermatol. 1983;119:874-875.
52. Hood AF, Hardegen GL, Zarate AR, et al. Kyrle's disease in patients with chronic renal failure. Arch Dermatol. 1982;118:85-88.
53. Nickoloff BJ, Noodleman FR, Abel EA. Perforating pseudoxanthoma elasticum associated with chronic renal failure and hemodialysis. Arch Dermatol. 1985;121:1321-1322.
54. Pietsch H, Jost G, Frenzel T, et al. Efficacy and safety of lanthanoids as X-ray contrast agents. Eur J Radiol. 2009. [Epub ahead of print.]
55. Gong H. Uncommon causes of occupational interstitial lung diseases. Curr Opin Pulm Med. 1996;2:405-411.
56. Steger-Hartmann T, Raschke M, Riefke B, et al. The involvement of proinflammatory cytokines in nephrogenic systemic fibrosis-a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol. 2009;61:537-542.
57. Wermuth PJ, Del Galdo F, Jiménez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum. 2009;60:1508-1518.
58. Ortonne N, Lipsker D, Chantrel F, et al. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol. 2004;150:1050-1052.
59. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest. 2007;87:858-870.
60. Strieter RM, Keeley EC, Hughes MA, et al. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol. 2009;86:1111-1118.
61. Ashcroft GS, Mills SJ, Ashworth JJ. Ageing and wound healing. Biogerontology. 2002;3:337-345.
62. Gosain A, DiPietro LA. Aging and wound healing. World J Surg. 2004;28: 321-326.
63. Wicke C, Bachinger A, Coerper S, et al. Aging influences wound healing in patients with chronic lower extremity wounds treated in a specialized wound care center. Wound Repair Regen. 2009;17:25-33.
64. Barta CA, Sachs-Barrable K, Jia J, et al. Lanthanide containing compounds for therapeutic care in bone resorption disorders. Dalton Trans. 2007:5019-5030